IRMD insider Form 4 shows modest director stock sales

Rhea-AI Filing Summary

IRADIMED CORP director reports open-market stock sales. A reporting person serving as a director of IRADIMED CORP (ticker IRMD) disclosed several open-market sales of common stock on 11/20/2025. The transactions, all coded as sales, totaled 3,000 shares at prices ranging from $88.00 to $88.50 per share. After these trades, the director beneficially owned 30,545 shares of IRADIMED common stock in direct ownership. This filing is a routine Form 4 disclosure of insider trading activity and does not describe any company-level operational or financial changes.

Insights

Equity Markets & Insider Transactions Analyst

Director makes modest, routine stock sales at around $88 per share.

A director of IRADIMED CORP (IRMD) reported multiple open-market sales of common stock on 11/20/2025. The trades, all marked with transaction code "S" for sale, were executed at prices between $88.00 and $88.50 per share, totaling 3,000 shares sold.

Following these transactions, the director's beneficial ownership stood at 30,545 shares held directly. This level of activity is relatively small in absolute terms and the disclosure is a standard compliance event under Section 16 reporting rules, rather than a change in the company’s operations or capital structure.

Because the content focuses only on personal trading activity and does not include financial results, guidance, or corporate actions, the information is best viewed as administratively informative rather than a thesis-changing development for IRMD.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAWKINS JAMES B

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		S		28	D	$88.29	33,517	D
Common Stock	11/20/2025		S		100	D	$88.28	33,417	D
Common Stock	11/20/2025		S		100	D	$88.26	33,317	D
Common Stock	11/20/2025		S		772	D	$88.2	32,545	D
Common Stock	11/20/2025		S		1,000	D	$88.5	31,545	D
Common Stock	11/20/2025		S		1,000	D	$88	30,545	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ James B Hawkins	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRADIMED CORP (IRMD) disclose in this Form 4?

A director of IRADIMED CORP disclosed several open-market sales of common stock on 11/20/2025, all reported as code "S" transactions.

How many IRADIMED (IRMD) shares did the director sell and at what prices?

The director sold a total of 3,000 shares of IRADIMED common stock at prices ranging from $88.00 to $88.50 per share.

How many IRADIMED CORP (IRMD) shares does the director own after the transactions?

After the reported sales, the director beneficially owned 30,545 shares of IRADIMED common stock in direct ownership.

What is the director’s relationship to IRADIMED CORP (IRMD)?

The reporting person is identified as a director of IRADIMED CORP, according to the relationship section of the filing.

Does this IRADIMED (IRMD) Form 4 indicate any change in company operations or strategy?

No. The Form 4 only reports the director’s personal stock sales and does not describe any changes in IRADIMED CORP’s operations, strategy, or financial results.

Are there any derivative securities reported for the IRADIMED (IRMD) insider?

No derivative securities are reported as acquired, disposed of, or beneficially owned; the detailed activity relates only to common stock in Table I.